With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS hopes that compelling survival data and unmet need will accelerate European patients' access to its novel advanced melanoma drug Yervoy.